Is This a 737 Max Moment for Brolucizumab?

The first reports of severe uveitis and occlusive retinal vasculitis associated with the use of brolucizumab (Beovu; Novartis, East Hanover, New Jersey, USA) appeared in early February of 2020, and more have appeared since then. Novartis sent information on the postapproval development to users on February 25 and updates have followed.1 Twenty-six cases associated with 70,000 injections and 37,000 treated patients were reported by March 27, 2020, in a report by the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Editorial Source Type: research